Progress in Immunopharmacy
A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Immunology and Immunotherapy".
Deadline for manuscript submissions: 31 August 2025 | Viewed by 284
Special Issue Editors
Interests: inflammation pharmacology; drug discovery; cancer biology
Special Issues, Collections and Topics in MDPI journals
Interests: cancer physiology; immunopharmacology; translational medicine
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
This Special Issue, "Progress in Immunopharmacy", aims to explore recent advancements and emerging trends in the field of immunopharmacy and immunopharmacology, encompassing the study of immune system-targeting pharmacological interventions, including immunomodulatory drugs, vaccines, and immunotherapies. It seeks to provide a platform for researchers to showcase their innovative research findings, methodologies, and discoveries related to immunopharmacy and immunopharmacology. The topics of interest may include but are not limited to the development of novel immunotherapeutic agents, immunopharmacological mechanisms, drug interactions with the immune system, personalized immunopharmacotherapy approaches, and clinical immunopharmacy applications in various disease settings. By highlighting the latest progress in immunopharmacy, this Special Issue aims to stimulate further research, foster collaboration, and contribute to the advancement of pharmacotherapy tailored to immune response modulation for improved health outcomes.
Dr. Po-Jen Chen
Dr. Shun-Hua Chen
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- immunopharmacy
- immunopharmacology
- immunomodulation
- pharmacological intervention
- immunotherapy
- drug–immune system interaction
- vaccine development
- personalized pharmacotherapy
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue policies can be found here.
